Hyundai Pharm said Wednesday it has received approval from the Ministry of Food and Drug Safety (MFDS) for Niserin Tab 30mg (nicergoline), a brain function enhancer.

Nicergoline inhibits alpha-1 adrenergic receptors, resulting in peripheral vasodilation to increase blood circulation in the brain.

Nicergoline has been used as a first-line treatment for dementia as it is effective in treating symptoms, such as impaired memory, concentration, and judgment as well as lack of activeness due to vascular dementia, Hyundai Pharm said.

Common side effects of nicergoline include mild gastrointestinal upset, including nausea or abdominal discomfort. Dizziness or headache may also occur due to its vasodilating effects.

"Recently, existing drugs for brain function enhancement have reached the point of de facto retirement due to the reduction or elimination of benefits through reimbursement reassessments,” a Hyundai Pharm official said. “Niserin will provide more diverse treatment options for healthcare providers and patients."

Hyundai Pharm continues its research to develop treatment for people with dementia by launching Hypezil powder, which improves medication adherence for dementia patients, and Hypezil Tab 3mg, a low-dose formulation for improved safety and tolerability.